Cargando…

TRPS1 expression in cytokeratin 5 expressing triple negative breast cancers, its value as a marker of breast origin

The lack of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 expression in breast cancer (BC) is the basis for the categorization of the tumour as triple negative breast carcinoma (TNBC). The majority of TNBCs are aggressive tumours with common metastases and de...

Descripción completa

Detalles Bibliográficos
Autores principales: Almási, Szintia, Kuthi, Levente, Sejben, Anita, Vörös, András, Nagy, Ákos, Zombori, Tamás, Cserni, Gábor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10156897/
https://www.ncbi.nlm.nih.gov/pubmed/37012444
http://dx.doi.org/10.1007/s00428-023-03535-4
_version_ 1785036639510200320
author Almási, Szintia
Kuthi, Levente
Sejben, Anita
Vörös, András
Nagy, Ákos
Zombori, Tamás
Cserni, Gábor
author_facet Almási, Szintia
Kuthi, Levente
Sejben, Anita
Vörös, András
Nagy, Ákos
Zombori, Tamás
Cserni, Gábor
author_sort Almási, Szintia
collection PubMed
description The lack of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 expression in breast cancer (BC) is the basis for the categorization of the tumour as triple negative breast carcinoma (TNBC). The majority of TNBCs are aggressive tumours with common metastases and decreased expression of markers that could help in identifying the metastatic lesion as of mammary origin. Breast markers, such as gross cystic disease fluid protein-15 (GCDPF-15), GATA binding protein 3 (GATA3), mammaglobin (MGB) and SOX10, are not uniquely specific to BC. Our aim was to evaluate trichorhinophalangeal syndrome type 1 (TRPS1) protein as a breast marker in a series of cytokeratin-5-expressing TNBC, mostly corresponding to basal-like TNBCs, previously characterized for the expression of other breast markers. One hundred seventeen TNBCs in tissue microarrays were immunostained for TRPS1. The cut-off for positivity was ≥ 10%. The reproducibility of this classification was also assessed. TRPS1 positivity was detected in 92/117 (79%) cases, and this exceeded the expression of previously tested markers like SOX10 82 (70%), GATA3 11 (9%), MGB 10 (9%) and GCDFP-15 7 (6%). Of the 25 TRPS1-negative cases, 11 were positive with SOX10, whereas 5 to 6 dual negatives displayed positivity for the other makers. The evaluation showed substantial agreement. Of the five markers compared, TRPS1 seems the most sensitive marker for the mammary origin of CK5-expressing TNBCs. Cases that are negative are most often labelled with SOX10, and the remainder may still demonstrate positivity for any of the 3 other markers. TRPS1 has a place in breast marker panels. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00428-023-03535-4.
format Online
Article
Text
id pubmed-10156897
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-101568972023-05-05 TRPS1 expression in cytokeratin 5 expressing triple negative breast cancers, its value as a marker of breast origin Almási, Szintia Kuthi, Levente Sejben, Anita Vörös, András Nagy, Ákos Zombori, Tamás Cserni, Gábor Virchows Arch Original Article The lack of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 expression in breast cancer (BC) is the basis for the categorization of the tumour as triple negative breast carcinoma (TNBC). The majority of TNBCs are aggressive tumours with common metastases and decreased expression of markers that could help in identifying the metastatic lesion as of mammary origin. Breast markers, such as gross cystic disease fluid protein-15 (GCDPF-15), GATA binding protein 3 (GATA3), mammaglobin (MGB) and SOX10, are not uniquely specific to BC. Our aim was to evaluate trichorhinophalangeal syndrome type 1 (TRPS1) protein as a breast marker in a series of cytokeratin-5-expressing TNBC, mostly corresponding to basal-like TNBCs, previously characterized for the expression of other breast markers. One hundred seventeen TNBCs in tissue microarrays were immunostained for TRPS1. The cut-off for positivity was ≥ 10%. The reproducibility of this classification was also assessed. TRPS1 positivity was detected in 92/117 (79%) cases, and this exceeded the expression of previously tested markers like SOX10 82 (70%), GATA3 11 (9%), MGB 10 (9%) and GCDFP-15 7 (6%). Of the 25 TRPS1-negative cases, 11 were positive with SOX10, whereas 5 to 6 dual negatives displayed positivity for the other makers. The evaluation showed substantial agreement. Of the five markers compared, TRPS1 seems the most sensitive marker for the mammary origin of CK5-expressing TNBCs. Cases that are negative are most often labelled with SOX10, and the remainder may still demonstrate positivity for any of the 3 other markers. TRPS1 has a place in breast marker panels. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00428-023-03535-4. Springer Berlin Heidelberg 2023-04-03 2023 /pmc/articles/PMC10156897/ /pubmed/37012444 http://dx.doi.org/10.1007/s00428-023-03535-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Almási, Szintia
Kuthi, Levente
Sejben, Anita
Vörös, András
Nagy, Ákos
Zombori, Tamás
Cserni, Gábor
TRPS1 expression in cytokeratin 5 expressing triple negative breast cancers, its value as a marker of breast origin
title TRPS1 expression in cytokeratin 5 expressing triple negative breast cancers, its value as a marker of breast origin
title_full TRPS1 expression in cytokeratin 5 expressing triple negative breast cancers, its value as a marker of breast origin
title_fullStr TRPS1 expression in cytokeratin 5 expressing triple negative breast cancers, its value as a marker of breast origin
title_full_unstemmed TRPS1 expression in cytokeratin 5 expressing triple negative breast cancers, its value as a marker of breast origin
title_short TRPS1 expression in cytokeratin 5 expressing triple negative breast cancers, its value as a marker of breast origin
title_sort trps1 expression in cytokeratin 5 expressing triple negative breast cancers, its value as a marker of breast origin
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10156897/
https://www.ncbi.nlm.nih.gov/pubmed/37012444
http://dx.doi.org/10.1007/s00428-023-03535-4
work_keys_str_mv AT almasiszintia trps1expressionincytokeratin5expressingtriplenegativebreastcancersitsvalueasamarkerofbreastorigin
AT kuthilevente trps1expressionincytokeratin5expressingtriplenegativebreastcancersitsvalueasamarkerofbreastorigin
AT sejbenanita trps1expressionincytokeratin5expressingtriplenegativebreastcancersitsvalueasamarkerofbreastorigin
AT vorosandras trps1expressionincytokeratin5expressingtriplenegativebreastcancersitsvalueasamarkerofbreastorigin
AT nagyakos trps1expressionincytokeratin5expressingtriplenegativebreastcancersitsvalueasamarkerofbreastorigin
AT zomboritamas trps1expressionincytokeratin5expressingtriplenegativebreastcancersitsvalueasamarkerofbreastorigin
AT csernigabor trps1expressionincytokeratin5expressingtriplenegativebreastcancersitsvalueasamarkerofbreastorigin